These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 33394867)
1. Limited reliability of heart rate as a sympathetic marker in chronic kidney disease. Dell'Oro R; Quarti-Trevano F; Seravalle G; Bertoli S; Lovati C; Mancia G; Grassi G J Hypertens; 2021 Jul; 39(7):1429-1434. PubMed ID: 33394867 [TBL] [Abstract][Full Text] [Related]
2. Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. Quarti Trevano F; Seravalle G; Macchiarulo M; Villa P; Valena C; Dell'Oro R; Mancia G; Grassi G J Hypertens; 2017 Aug; 35(8):1685-1690. PubMed ID: 28350577 [TBL] [Abstract][Full Text] [Related]
3. Sympathetic activation and heart rate thresholds for cardiovascular risk in chronic kidney disease. Grassi G; Fowler B; Scali B; Rossi F; Motto E; Pieruzzi F; Mancia G J Hypertens; 2022 Aug; 40(8):1530-1536. PubMed ID: 35792492 [TBL] [Abstract][Full Text] [Related]
4. Heart rate as a sympathetic marker during acute adrenergic challenge. Grassi G; Seravalle G; Bolla G; Quarti-Trevano F; Dell'Oro R; Arenare F; Mancia G J Hypertens; 2008 Jan; 26(1):70-5. PubMed ID: 18090542 [TBL] [Abstract][Full Text] [Related]
5. Heart rate thresholds for cardiovascular risk and sympathetic activation in the metabolic syndrome. Seravalle G; Vanoli J; Molisano C; Merati V; Grassi G Acta Diabetol; 2022 Nov; 59(11):1429-1435. PubMed ID: 35904642 [TBL] [Abstract][Full Text] [Related]
6. Elevated heart rate as sympathetic biomarker in human obesity. Seravalle G; Facchetti R; Cappellini C; Annaloro A; Gelfi E; Grassi G Nutr Metab Cardiovasc Dis; 2022 Oct; 32(10):2367-2374. PubMed ID: 35970685 [TBL] [Abstract][Full Text] [Related]
7. Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. Grassi G; Quarti-Trevano F; Seravalle G; Dell'Oro R; Facchetti R; Mancia G Hypertension; 2020 Aug; 76(2):577-582. PubMed ID: 32594806 [TBL] [Abstract][Full Text] [Related]
18. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Grassi G; Seravalle G; Turri C; Bolla G; Mancia G Hypertension; 2003 Mar; 41(3):558-62. PubMed ID: 12623959 [TBL] [Abstract][Full Text] [Related]
19. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Leimbach WN; Wallin BG; Victor RG; Aylward PE; Sundlöf G; Mark AL Circulation; 1986 May; 73(5):913-9. PubMed ID: 3698236 [TBL] [Abstract][Full Text] [Related]
20. Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. Grassi G; Seravalle G; Dell'Oro R; Facchini A; Ilardo V; Mancia G J Hypertens; 2004 Sep; 22(9):1747-53. PubMed ID: 15311103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]